Proactive Investors - Run By Investors For Investors

Medical expert discusses his experience working with Shield Therapeutics' Feraccru drug

Dr Fraser Cummings,  a consultant gastroenterologist at Southampton General Hospital, spoke to Proactive's Andrew Scott while in London.

''One of the big advantages of Feraccru is that it's extremely well tolerated in the actually quite difficult group of patients who've already failed oral therapies and are quite anxious about taking another iron tablet ... but our data shows that patients do tolerate it well and we hit the targets we're expecting from the drug''.

''With Feraccru we can get patients onto treatment very quickly and patients will then get the benefit of being made iron replete''.

US regulators have set a target date of July 27th to decide whether or not to approve Shield Therapeutics PLC’s (LON:STX) Feraccru drug.

 
Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full STX profile View Profile

Shield Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use